EP0402422A1 - Gewisse paf-antagonist/antihistamin-mischungen und verfahren - Google Patents

Gewisse paf-antagonist/antihistamin-mischungen und verfahren

Info

Publication number
EP0402422A1
EP0402422A1 EP89905952A EP89905952A EP0402422A1 EP 0402422 A1 EP0402422 A1 EP 0402422A1 EP 89905952 A EP89905952 A EP 89905952A EP 89905952 A EP89905952 A EP 89905952A EP 0402422 A1 EP0402422 A1 EP 0402422A1
Authority
EP
European Patent Office
Prior art keywords
carbon atoms
triazolo
formula
paf
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP89905952A
Other languages
English (en)
French (fr)
Inventor
M. Motasim Billah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP0402422A1 publication Critical patent/EP0402422A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EP89905952A 1988-04-27 1989-04-24 Gewisse paf-antagonist/antihistamin-mischungen und verfahren Pending EP0402422A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18653588A 1988-04-27 1988-04-27
US186535 1988-04-27

Publications (1)

Publication Number Publication Date
EP0402422A1 true EP0402422A1 (de) 1990-12-19

Family

ID=22685331

Family Applications (2)

Application Number Title Priority Date Filing Date
EP89304068A Expired - Lifetime EP0345931B1 (de) 1988-04-27 1989-04-24 Gewisse PAF-Antagonist/Antihistamin-Mischungen und Verfahren
EP89905952A Pending EP0402422A1 (de) 1988-04-27 1989-04-24 Gewisse paf-antagonist/antihistamin-mischungen und verfahren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP89304068A Expired - Lifetime EP0345931B1 (de) 1988-04-27 1989-04-24 Gewisse PAF-Antagonist/Antihistamin-Mischungen und Verfahren

Country Status (15)

Country Link
EP (2) EP0345931B1 (de)
JP (1) JPH0655673B2 (de)
KR (1) KR930009786B1 (de)
AT (1) ATE84724T1 (de)
AU (1) AU619555B2 (de)
CA (1) CA1327316C (de)
DE (1) DE68904475T2 (de)
DK (1) DK255190D0 (de)
ES (1) ES2044100T4 (de)
IE (1) IE63697B1 (de)
IL (1) IL90100A (de)
MY (1) MY106956A (de)
NZ (1) NZ228879A (de)
WO (1) WO1989010143A1 (de)
ZA (1) ZA893101B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30676A (en) * 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
US6277846B1 (en) * 1990-05-31 2001-08-21 Allergan Sales, Inc. Use of platelet activating factor antagonists as anti-pruritic agents
EP0469477B1 (de) * 1990-08-02 1995-09-20 F. Hoffmann-La Roche Ag Antiallergische Mischung
US5227378A (en) * 1990-08-02 1993-07-13 Hoffmann-La Roche Inc. Combination of PAF antagonists and LTD4 antagonists for the treatment of allergic reactions
FR2673842B1 (fr) * 1991-03-13 1993-12-24 Rhone Poulenc Rorer Sa Nouvelles compositions liquides a base de derives de la piperidine substitues en 1,4.
FR2684298B1 (fr) * 1991-12-03 1994-03-11 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques solides a base de derives de lapiperidine substitues en 1,4.
JP3060287B2 (ja) * 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
US8492376B2 (en) * 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539332A (en) * 1983-11-14 1985-09-03 Merck & Co., Inc. 2,5-Diaryl tetrahydrofurans and analogs thereof as PAF-antagonists
NZ211146A (en) * 1984-02-29 1987-10-30 Merck & Co Inc 2,5-diaryl-tetrahydrothiophene derivatives and pharmaceutical compositions
US4595693A (en) * 1984-06-04 1986-06-17 Merck & Co., Inc. Method of use of 2,5-diaryl tetrahydrofurans and analogs thereof as PAF-antagonists
DE3502392A1 (de) * 1985-01-25 1986-07-31 Boehringer Ingelheim KG, 6507 Ingelheim Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
US4910206A (en) * 1986-07-14 1990-03-20 Sandoz Pharmaceuticals Corp. 5-hetero-or aryl-substituted-imidazo(2,1-a)isoquinolines and their use as PAF receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8910143A1 *

Also Published As

Publication number Publication date
ATE84724T1 (de) 1993-02-15
NZ228879A (en) 1992-08-26
JPH0655673B2 (ja) 1994-07-27
ES2044100T4 (es) 1996-07-16
ZA893101B (en) 1989-12-27
DE68904475D1 (de) 1993-03-04
KR900700136A (ko) 1990-08-11
JPH03502097A (ja) 1991-05-16
ES2044100T3 (es) 1994-01-01
IL90100A (en) 1995-01-24
EP0345931B1 (de) 1993-01-20
AU3578289A (en) 1989-11-24
KR930009786B1 (ko) 1993-10-11
DK255190A (da) 1990-10-23
AU619555B2 (en) 1992-01-30
IE63697B1 (en) 1995-05-31
DK255190D0 (da) 1990-10-23
IL90100A0 (en) 1989-12-15
MY106956A (en) 1995-08-30
WO1989010143A1 (en) 1989-11-02
CA1327316C (en) 1994-03-01
DE68904475T2 (de) 1993-05-13
IE891362L (en) 1989-10-27
EP0345931A1 (de) 1989-12-13

Similar Documents

Publication Publication Date Title
JP3778923B2 (ja) ベンゾジアゼピンによる治療における改善
US5760061A (en) Methods of treating menstrual symptoms and compositions therefore
Steele et al. Double-Blind Comparison of the Antiemetic Effects of Nabilone and Prochlorperazine on Chemotherapy-Induced Emesis 1, 2, 3
JPH0621070B2 (ja) ジアゼピン含有医薬組成物
AU740875B2 (en) Novel use of compounds for anti-pruritic activity
EP0345931B1 (de) Gewisse PAF-Antagonist/Antihistamin-Mischungen und Verfahren
BENOWITZ et al. Depression of growth hormone and cortisol response to insulin-induced hypoglycemia after prolonged oral delta-9-tetrahydrocannabinol administration in man
US5334592A (en) Certain PAF antagonist antihistamine combinations and methods
US5705506A (en) Pharmaceutical compositions of alkylsulphonamides 5HT1 agonists for rectal administration
US4794112A (en) Acetaminophen/hydroxyzine analgesic combinations
US6455552B1 (en) Combination of a GABAA α5 inverse agonist and a muscarinic agonist
NL8002041A (nl) Werkwijze voor het bereiden van een analgetisch en myotonolytisch geneesmiddel.
CA2162919C (en) Rectal compositions
CA2262267C (en) Anti-migraine pharmaceutical compositions and process of using
US4801589A (en) Method for suppressing the immune response
US20060079513A1 (en) Methods and compositions including methscopolamine nitrate
KR960005145B1 (ko) 고혈압 및 울혈성 심부전증 치료용 약학적 조성물
JPH11513386A (ja) β−受容体遮断薬とオピオイドとの新規な組合せ物
US20060079514A1 (en) Methods and compositions including methscopolamine bromide
CA2062094C (en) Method of treating mania
RU2003106417A (ru) Применение комбинации витаминов для лечения первичных головных болей
MXPA00003775A (en) Novel use of compounds for anti-pruritic activity
JPH0132806B2 (de)
JPH0610133B2 (ja) 増殖過剰性皮膚疾患処置用組成物
MXPA00009614A (en) Combination effective for the treatment of impotence comprising a potassium-channel-opener and a cgmp elevator

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 19901010

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

XX Miscellaneous (additional remarks)

Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT89304068.3/0345931 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 18.03.91.